 |
|
|
| |
Once-Daily Maraviroc (MVC) + Atazanavir/Ritonavir(ATV/r) vs. Emtricitabine/Tenofovir(TDF/FTC) + ATV/r in Treatment Naïve Patients: A Week 24 Planned Interim Analysis
|
| |
| |
Reported by Jules Levin
18th Intl AIDS Conference July 18-23 2010 Vienna Austria
Anthony Mills1, Donna Mildvan2, Daniel Podzamczer3, Gerd Fätkenheuer4, Manuel Leal5, Soe Than6, Srinivas Valluri6, Charles Craig7, Jayvant Heera6, Simon Portsmouth6
1Los Angeles, CA; 2Beth Israel Medical Center Division of Infectious Diseases, New York, NY; 3HIV Unit, Infectious Disease Service, Hospital Unversitaride Bellvitge, Barcelona, Spain; 4UniversitaetKoeln, Koeln, Germany; 5Laboratory of Immunovirology, Biomedicine Institute of Seville (IBIS), Infectious Diseases Service, Virgendel RocioUniversity Hospital, Sevilla, Spain; 6Pfizer Inc, New York, NY USA: 7Pfizer, Sandwich, Kent UK.
|
| |
|
|
|
|
|
